Related Experiment Video
Updated: Jul 18, 2026
In Vivo Forward Genetic Screen to Identify Novel Neuroprotective Genes in Drosophila melanogaster
Published on: July 11, 2019
[Complex influence of pharmacological agents on degenerative processes in brain of Drosophila melanogaster mutants]
Abstract:
A scheme of complex administration of drugs in the order neuroprotector + neuroactivator + neuroretarder for the treatment of neurodegenerative processes in the brain has been elaborated and tested on a model object representing neurodegenerative mutants of Drosophila melanogaster. The appearance of changes in the brain was delayed when drugs were used separately: donepezil hydrochloride (arisept), 10 - 11 days, epinephrine and nimodipine, 1 - 2 days. The treatment of flies with the same drugs in the order arisept + epinephrine + nimodipine leads to the complete regeneration of D. melanogaster brain tissue to within 15 days of imago life.
Insights
A novel drug combination therapy effectively reverses neurodegeneration in Drosophila melanogaster models. This treatment strategy shows complete brain tissue regeneration, offering new hope for neurodegenerative disease therapies.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Neurodegenerative diseases pose a significant challenge.
- Current treatments offer limited efficacy.
- A complex drug administration scheme was investigated.
Purpose of the Study:
- To develop and test a novel drug combination for neurodegenerative processes.
- To evaluate the efficacy of sequential drug administration in a model organism.
Main Methods:
- Utilized Drosophila melanogaster as a model for neurodegeneration.
- Administered drugs sequentially: neuroprotector (donepezil hydrochloride), neuroactivator (epinephrine), and neuroretarder (nimodipine).
- Assessed brain tissue regeneration and delay in degenerative changes.
Main Results:
- Separate drug administration delayed brain changes by 1-11 days.
- Combined therapy (arisept + epinephrine + nimodipine) resulted in complete brain tissue regeneration within 15 days.
- Demonstrated significant therapeutic potential of the combined drug regimen.
Conclusions:
- The developed drug administration scheme is effective in treating neurodegeneration.
- Sequential administration of neuroprotectors, neuroactivators, and neuroretarders promotes complete brain regeneration.
- This approach holds promise for future neurodegenerative disease therapies.
